New Search

If you are not happy with the results below please do another search

1122 search results for:

156

Emmes acquires VaxTRIALS

Rockville, Maryland, US-based Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, has acquired VaxTRIALS. Headquartered in Panama City, Panama, VaxTRIALS’ 160+ staff members manage and monitor vaccine clinical trial activities throughout Latin America.

158

SpliceBio collaborates with Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease

SpliceBio, a Barcelona, Spain-based genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has signed an exclusive collaboration and licensing agreement with Philadelphia, Pennsylvania-based Spark Therapeutics to utilize SpliceBio’s proprietary protein splicing platform to develop a gene therapy for an undisclosed inherited retinal disease.

159

Gilead and Assembly Biosciences partner to develop next-gen therapeutics

Gilead Sciences has entered into a 12-year partnership with Assembly Biosciences, a biotechnology company developing antiviral therapeutics targeting serious viral diseases. The partnership, announced 17 October, aims to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D […]

160

Mogrify raises $46m to advance reprogramming therapies

Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, has closed an additional US$10 million of its Series A financing, bringing the total raised to $46 million in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical […]